{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:31:47Z","timestamp":1779244307127,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd010298","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000}}],"reference-count":175,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010298.pub2","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T16:00:05Z","timestamp":1428768005000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis"],"prefix":"10.1002","volume":"2015","author":[{"given":"Arturo J","family":"Mart\u00ed-Carvajal","sequence":"first","affiliation":[{"name":"Iberoamerican Cochrane Network; Valencia Venezuela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidhu","family":"Anand","sequence":"additional","affiliation":[{"name":"University of Minnesota; Department of Medicine; 420 Delaware Street SE Mayo Mail Code 195 Minneapolis MN USA 55455"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Sol\u00e0","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 171 - Edifici Casa de Convalesc\u00e8ncia Barcelona Catalunya Spain 08041"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,10]]},"reference":[{"key":"10.1002\/14651858.CD010298.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Mesa R Verstovsek S Gupta V Mascarenhas J Atallah E Sun W Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I Blood (ASH Annual Meeting Abstracts) 2012","DOI":"10.1182\/blood.V120.21.1733.1733"},{"issue":"10","key":"10.1002\/14651858.CD010298.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD010298.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/cncr.26129","article-title":"Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial","volume":"117","author":"Mesa","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD010298.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.leukres.2013.04.017","article-title":"Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study","volume":"37","author":"Mesa","year":"2013","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Talpaz M Paquette R Afrin L Hamburg S Jamieson K Terebelo H Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50\u2013100 x 10 9 \/L): a comparison to patients with normal or high starting platelet counts Blood (ASH Annual Meeting Abstracts) 2012","DOI":"10.1182\/blood.V120.21.176.176"},{"issue":"6","key":"10.1002\/14651858.CD010298.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Verstovsek S Mesa R Gotlib J Levy RS Gupta V DiPersio JF Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I Blood (ASH Annual Meeting Abstracts) 2012","DOI":"10.1182\/blood.V120.21.800.800"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Verstovsek S Mesa RA Gotlib J Levy R Gupta V DiPersio JF Clinical burden and progression of myelofibrosis in a controlled study population of placebo-treated patients (COMFORT-I) Blood (ASH Annual Meeting Abstracts) 2011","DOI":"10.1182\/blood.V118.21.5146.5146"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Verstovsek S Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT-I Blood 2011","DOI":"10.1182\/blood.V118.21.278.278"},{"issue":"4","key":"10.1002\/14651858.CD010298.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek","year":"2013","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Verstovsek S Mesa RA Gotlib JR Gupta V DiPersio JF Catalano JV for the COMFORT-I Investigators Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2012","DOI":"10.1200\/jco.2012.30.15_suppl.6624"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Verstovsek S Mesa RA Gotlib JR Levy RS Gupta V DiPersio JF Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1\/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF) Journal of Clinical Oncology 2011","DOI":"10.1200\/jco.2011.29.15_suppl.6500"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Cervantes F Kiladjian JJ Niederwieser D Sirulnik A Stalbovskaya V McQuity M Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) Blood (ASH Annual Meeting Abstracts) 2012","DOI":"10.1182\/blood.V120.21.801.801"},{"issue":"25","key":"10.1002\/14651858.CD010298.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"issue":"14","key":"10.1002\/14651858.CD010298.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Harrison C Kiladjian JJ Al-Ali HK Gisslinger H Waltzman R Stalbovskaya V Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF) http:\/\/www.oncuview.tv\/portals\/0\/linkedfiles\/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf","DOI":"10.1200\/jco.2011.29.18_suppl.lba6501"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Harrison CN Kiladjian J Al-Ali HK Gisslinger H Waltzman RJ Stalbovskaya V Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF) Journal of Clinical Oncology 2011 LBA6501","DOI":"10.1200\/jco.2011.29.18_suppl.lba6501"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Harrison CN Kiladjian J-J Al-Ali HK Gisslinger H Knoops L Waltzman RJ Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy Blood 2011","DOI":"10.1182\/blood.V118.21.795.795"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Harrison CN Kiladjian J-J Gisslinger H Niederwieser D Passamonti F Waltzman RJ Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT-II study Blood 2011","DOI":"10.1182\/blood.V118.21.279.279"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.12375","article-title":"Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy","volume":"162","author":"Harrison","year":"2013","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Kiladjian JJ Gisslinger H Passamonti F Niederwieser D Mendelson E Sirulnik LA Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study Journal of Clinical Oncology (ASCO Annual Meeting Proceedings) 2012","DOI":"10.1200\/jco.2012.30.15_suppl.6626"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0026|cit25","doi-asserted-by":"crossref","unstructured":"McMullin MF Harrison CN Niederwieser D Demuynck H Jakel N Sirulnik A The use of erythropoietic-stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF) Blood (ASH Annual Meeting Abstracts) 2012","DOI":"10.1182\/blood.V120.21.2838.2838"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0025|cit26","doi-asserted-by":"crossref","unstructured":"McMullin MF Harrison CN Niederwieser D Demuynck H J\u00e4ckel N Sirulnik A Anemia and the use of erythropoietic-stimulating agents with ruxolitinib in the COMFORT-II study Blood (ASH Annual Meeting Abstracts) 2011","DOI":"10.1182\/blood.V118.21.5147.5147"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10428194.2013.789507","article-title":"Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval","volume":"55","author":"Geyer","year":"2014","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/10428194.2013.802318","article-title":"Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis","volume":"55","author":"Verstovsek","year":"2014","journal-title":"Leukemia & Lymphoma"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD010298.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"TPS6642","DOI":"10.1200\/jco.2012.30.15_suppl.tps6642","article-title":"A phase Ib, open-label, dose-finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) and baseline platelets (PLTs) 50 to <100 x 109\/l","volume":"30","author":"Gisslinger","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010298.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD010298.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"TPS6640","DOI":"10.1200\/jco.2012.30.15_suppl.tps6640","article-title":"An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)","volume":"30","author":"Coutre","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/sj.leu.2404816","article-title":"A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia","volume":"21","author":"Mesa","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3324\/haematol.2013.087650","article-title":"Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies","volume":"99","author":"Mesa","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"10.1002\/14651858.CD010298.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Pardanani AD Gotlib J Jamieson C Cortes J Talpaz M Stone RM A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis: clinical response is accompanied by significant reduction in JAK2 V617F allele burden Blood (ASH Annual Meeting Abstracts) 2009","DOI":"10.1182\/blood.V114.22.755.755"},{"issue":"6","key":"10.1002\/14651858.CD010298.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1002\/14651858.CD010298.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD010298.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"TPS6630","DOI":"10.1200\/jco.2012.30.15_suppl.6630","article-title":"Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50\u2013100x109\/L","volume":"30","author":"Talpaz","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-8722-6-81","article-title":"Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts","volume":"6","author":"Talpaz","year":"2013","journal-title":"Journal of Hematology & Oncology"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Verstovsek S Kantarjian HM Estrov Z Cortes JE Thomas DA Kadia T Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy Blood (ASH Annual Meeting Abstracts) 2011","DOI":"10.1182\/blood.V118.21.793.793"},{"issue":"3","key":"10.1002\/14651858.CD010298.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.leukres.2013.12.006","article-title":"Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor","volume":"38","author":"Verstovsek","year":"2014","journal-title":"Leukemia Research"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD010298.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"TPS6639","DOI":"10.1200\/jco.2012.30.15_suppl.tps6639","article-title":"JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly","volume":"30","author":"Pardanani","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD010298.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"issue":"7003","key":"10.1002\/14651858.CD010298.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/bmj.311.7003.485","article-title":"Absence of evidence is not evidence of absence","volume":"311","author":"Altman","year":"1995","journal-title":"BMJ"},{"issue":"7549","key":"10.1002\/14651858.CD010298.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD010298.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/sim.1687","article-title":"Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses","volume":"23","author":"Austin","year":"2004","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/B978-1-4377-1604-7.00160-3","article-title":"The peripheral blood smear","volume-title":"Goldman's Cecil Medicine","author":"Bain","year":"2012"},{"issue":"4","key":"10.1002\/14651858.CD010298.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010298.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Barosi G Cervantes F Ben-Yehuda D Panagiotidis P Perez JR Orlando-Harper ND A ruxolitinib individual supply program for patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis Blood (ASH Annual Meeting Abstracts) 2011","DOI":"10.1182\/blood.V118.21.5170.5170"},{"issue":"10","key":"10.1002\/14651858.CD010298.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/14656566.2011.568939","article-title":"Therapeutic approaches in myelofibrosis","volume":"12","author":"Barosi","year":"2011","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"15","key":"10.1002\/14651858.CD010298.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2012.466","article-title":"Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective","volume":"307","author":"Basch","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2010.254","article-title":"A phase-2 trial of low-dose pomalidomide in myelofibrosis","volume":"25","author":"Begna","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD010298.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn3475","article-title":"Power failure: why small sample size undermines the reliability of neuroscience","volume":"14","author":"Button","year":"2013","journal-title":"Nature Reviews Neuroscience"},{"issue":"8","key":"10.1002\/14651858.CD010298.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD010298.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1358\/dot.2003.39.7.799441","article-title":"Darbepoetin alfa: a novel erythropoiesis-stimulating protein","volume":"39","author":"Cases","year":"2003","journal-title":"Drugs of Today"},{"issue":"13","key":"10.1002\/14651858.CD010298.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD010298.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/CCO.0b013e32834bb83f","article-title":"Advances in the understanding and management of primary myelofibrosis","volume":"23","author":"Cervantes","year":"2011","journal-title":"Current Opinion in Oncology"},{"issue":"9861","key":"10.1002\/14651858.CD010298.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(12)62160-6","article-title":"SPIRIT 2013: new guidance for content of clinical trial protocols","volume":"381","author":"Chan","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD010298.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0065|cit65","unstructured":"Biostat, Inc Comprehensive Meta-Analysis 2005"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0066|cit66","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis 2011"},{"issue":"5","key":"10.1002\/14651858.CD010298.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1590\/S1020-49892000001000005","article-title":"[Categorizing variables in the statistical analysis of data: consequences for interpreting the results]","volume":"8","author":"Cumsille","year":"2000","journal-title":"Revista Panamericana de Salud P\u00fablica"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0068|cit68","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration Available from www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD010298.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"e58711","DOI":"10.1371\/journal.pone.0058711","article-title":"Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials","volume":"8","author":"Djulbegovic","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/ajkd.2001.26111","article-title":"Why is erythropoietin made in the kidney? The kidney functions as a critmeter","volume":"38","author":"Donnelly","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD010298.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/jme.2007.022467","article-title":"Evaluating solutions to sponsorship bias","volume":"34","author":"Doucet","year":"2008","journal-title":"Journal of Medical Ethics"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0073|cit73","unstructured":"Food Drug Administration Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2007 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071590.pdf"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pst.331","article-title":"Consequences of dichotomization","volume":"8","author":"Fedorov","year":"2009","journal-title":"Pharmaceutical Statistics"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0075|cit75","unstructured":"Fermi Paradox www.crystalinks.com\/fermiparadox.html"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0076|cit76","first-page":"1149","article-title":"Essential thrombocythemia","volume-title":"Hoffman: Hematology: Basic Principles and Practice","author":"Finazzi","year":"2008"},{"issue":"13","key":"10.1002\/14651858.CD010298.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1056\/NEJM197809282991304","article-title":"The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 \"negative\" trials","volume":"299","author":"Freiman","year":"1978","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMp1207437","article-title":"Getting the methods right--the foundation of patient-centered outcomes research","volume":"367","author":"Gabriel","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1136\/bmj.e318","article-title":"Outcomes that matter to patients","volume":"344","author":"Godlee","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD010298.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2125.2008.03272.x","article-title":"Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?","volume":"66","author":"Golder","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0081|cit81","unstructured":"McMaster University GRADEpro 2014"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/epirev\/24.1.4","article-title":"Design of randomized trials","volume":"24","author":"Green","year":"2002","journal-title":"Epidemiologic Reviews"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0083|cit83","volume-title":"Wintrobe's Clinical Hematology","author":"Greer","year":"2009"},{"issue":"4","key":"10.1002\/14651858.CD010298.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010298.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines: 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence - inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence - indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence - publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010298.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010298.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines 12. Preparing Summary of findings tables - binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1471-0528.2008.02011.x","article-title":"Intrapartum amnioinfusion for meconium-stained amniotic fluid: evidence for small study effect bias?","volume":"116","author":"Hemming","year":"2009","journal-title":"BJOG"},{"issue":"11","key":"10.1002\/14651858.CD010298.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jclinepi.2010.01.010","article-title":"Assessing the impact of attrition in randomized controlled trials","volume":"63","author":"Hewitt","year":"2010","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0096|cit96","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0097|cit97","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0098|cit98","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0099|cit99","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/sim.4088","article-title":"Sequential methods for random-effects meta-analysis","volume":"30","author":"Higgins","year":"2011","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0101|cit101","first-page":"1125","article-title":"Primary myelofibrosis","volume-title":"Hoffman: Hematology: Basic Principles and Practice","author":"Hoffman","year":"2008"},{"issue":"5","key":"10.1002\/14651858.CD010298.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","article-title":"Conventional cytogenetics in myelofibrosis: literature review and discussion","volume":"82","author":"Hussein","year":"2009","journal-title":"European Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD010298.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD010298.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false","volume":"2","author":"Ioannidis","year":"2005","journal-title":"PLoS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010298.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/EDE.0b013e31818131e7","article-title":"Why most discovered true associations are inflated","volume":"19","author":"Ioannidis","year":"2008","journal-title":"Epidemiology"},{"issue":"3-4","key":"10.1002\/14651858.CD010298.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jrsm.19","article-title":"The art of getting it wrong","volume":"1","author":"Ioannidis","year":"2010","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2288-8-60","article-title":"Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions","volume":"8","author":"J\u00f8rgensen","year":"2008","journal-title":"BMC Medical Research Methodology"},{"issue":"5","key":"10.1002\/14651858.CD010298.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5694\/j.1326-5377.2002.tb04759.x","article-title":"Determining the sample size in a clinical trial","volume":"177","author":"Kirby","year":"2002","journal-title":"Medical Journal of Australia"},{"issue":"3","key":"10.1002\/14651858.CD010298.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jacc.2012.02.048","article-title":"From hot hands to declining effects: the risks of small numbers","volume":"60","author":"Lauer","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0111|cit111","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7400","key":"10.1002\/14651858.CD010298.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"Lexchin","year":"2003","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub2","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1037\/1082-989X.7.1.19","article-title":"On the practice of dichotomization of quantitative variables","volume":"7","author":"MacCallum","year":"2002","journal-title":"Psychological Methods"},{"issue":"11","key":"10.1002\/14651858.CD010298.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"24","key":"10.1002\/14651858.CD010298.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2013-02-482232","article-title":"A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis","volume":"121","author":"Mascarenhas","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.leukres.2009.04.011","article-title":"Hypothesis: how do JAK2-inhibitors work in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leukemia Research"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leukemia Research"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.21598","article-title":"Phase1\/-2 study of Pomalidomide in myelofibrosis","volume":"85","author":"Mesa","year":"2010","journal-title":"American Journal of Hematology"},{"issue":"22","key":"10.1002\/14651858.CD010298.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/10428194.2012.710905","article-title":"The evolving treatment paradigm in myelofibrosis","volume":"54","author":"Mesa","year":"2013","journal-title":"Leukemia & Lymphoma"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrd3652","article-title":"Ruxolitinib","volume":"11","author":"Mesa","year":"2012","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"9128","key":"10.1002\/14651858.CD010298.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD010298.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD010298.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/0003-4819-140-10-200405180-00009","article-title":"Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting","volume":"140","author":"Nebeker","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010298.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"American Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon.11.81","article-title":"Ruxolitinib: a new JAK1\/2 inhibitor that offers promising options for treatment of myelofibrosis","volume":"7","author":"Ostojic","year":"2011","journal-title":"Future Oncology"},{"issue":"11","key":"10.1002\/14651858.CD010298.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1358\/dot.2011.47.11.1708829","article-title":"Ruxolitinib for the treatment of myelofibrosis","volume":"47","author":"Ostojic","year":"2011","journal-title":"Drugs of Today"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0130|cit130","first-page":"95","article-title":"Ruxolitinib for the treatment of myelofibrosis: its clinical potential","volume":"8","author":"Ostojic","year":"2012","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOH.0b013e3283439964","article-title":"Targeting myeloproliferative neoplasms with JAK inhibitors","volume":"18","author":"Pardanani","year":"2011","journal-title":"Current Opinion in Hematology"},{"issue":"7","key":"10.1002\/14651858.CD010298.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/leu.2012.21","article-title":"Ruxolitinib for myelofibrosis therapy: current context, pros and cons","volume":"26","author":"Pardanani","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOH.0b013e32834ff575","article-title":"New generation small-molecule inhibitors in myeloproliferative neoplasms","volume":"19","author":"Passamonti","year":"2012","journal-title":"Current Opinion in Hematology"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.sbi.2011.11.007","article-title":"The two faces of Janus: functional interactions and protein aggregation","volume":"22","author":"Pastore","year":"2012","journal-title":"Current Opinion in Structural Biology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0136|cit136","unstructured":"Patient-Centered Outcomes Research Institute (PCORI) Preliminary draft methodology report: \"Our questions, our decisions: Standards for patient-centered outcomes research\", 2012 http:\/\/www.pcori.org\/assets\/Preliminary-Draft-Methodology-Report.pdf 1 61"},{"issue":"26","key":"10.1002\/14651858.CD010298.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/sim.5354","article-title":"Dichotomising continuous data while retaining statistical power using a distributional approach","volume":"31","author":"Peacock","year":"2012","journal-title":"Statistics in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD010298.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jclinepi.2010.12.012","article-title":"Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects","volume":"64","author":"Pereira","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD010298.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"580-93, 661-6","DOI":"10.1016\/S0197-2456(97)00051-2","article-title":"Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis","volume":"18","author":"Pogue","year":"1997","journal-title":"Controlled Clinical Trials"},{"issue":"9095","key":"10.1002\/14651858.CD010298.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(97)08461-4","article-title":"Overcoming the limitations of current meta-analysis of randomised controlled trials","volume":"351","author":"Pogue","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0141|cit141","volume-title":"A Dictionary of Epidemiology","author":"Porta","year":"2008"},{"issue":"4","key":"10.1002\/14651858.CD010298.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/jnci\/djn515","article-title":"Surrogate and mediating endpoints: current status and future directions","volume":"101","author":"Prentice","year":"2009","journal-title":"Journal of the National Cancer Institute"},{"issue":"28","key":"10.1002\/14651858.CD010298.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD010298.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1517\/14656566.2011.588948","article-title":"Management of myelofibrosis - where next?","volume":"12","author":"Qureshi","year":"2011","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1756-8722-5-43","article-title":"Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors","volume":"5","author":"Randhawa","year":"2012","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0146|cit146","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"6","key":"10.1002\/14651858.CD010298.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"17","key":"10.1002\/14651858.CD010298.pub2-BIB0148|cit148","first-page":"295","article-title":"The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication","volume":"107","author":"Schott","year":"2010","journal-title":"Deutsches Arzteblatt International"},{"issue":"16","key":"10.1002\/14651858.CD010298.pub2-BIB0149|cit149","first-page":"279","article-title":"The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials","volume":"107","author":"Schott","year":"2010","journal-title":"Deutsches Arzteblatt International"},{"issue":"5","key":"10.1002\/14651858.CD010298.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD010298.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.bcp.2011.12.024","article-title":"The many faces of Janus kinase","volume":"83","author":"Seavey","year":"2012","journal-title":"Biochemical Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD010298.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF03345745","article-title":"Androgens and erythropoiesis: past and present","volume":"32","author":"Shahani","year":"2009","journal-title":"Journal of Endocrinological Investigation"},{"issue":"6","key":"10.1002\/14651858.CD010298.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/CCO.0b013e32834d1b22","article-title":"Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms","volume":"23","author":"Stein","year":"2011","journal-title":"Current Opinion in Oncology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD010298.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/070674370204700307","article-title":"Breaking up is hard to do: The heartbreak of dichotomizing continuous data","volume":"47","author":"Streiner","year":"2002","journal-title":"Canadian Journal of Psychiatry"},{"issue":"27","key":"10.1002\/14651858.CD010298.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"13","key":"10.1002\/14651858.CD010298.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood-2010-11-315614","article-title":"How I treat myelofibrosis","volume":"117","author":"Tefferi","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.22210","article-title":"Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management","volume":"86","author":"Tefferi","year":"2011","journal-title":"American Journal of Hematology"},{"issue":"15","key":"10.1002\/14651858.CD010298.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of treatment with ruxolitinib in myelofibrosis","volume":"365","author":"Tefferi","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clinic Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD010298.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.blre.2011.06.002","article-title":"JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective","volume":"25","author":"Tefferi","year":"2011","journal-title":"Blood Reviews"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD010298.pub2-BIB0163|cit163","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD010298.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000101708","article-title":"Myelofibrosis - what's in a name? Consensus on definition and EUMNET grading","volume":"74","author":"Thiele","year":"2007","journal-title":"Pathobiology"},{"issue":"5","key":"10.1002\/14651858.CD010298.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1358\/dnp.2005.18.5.904198","article-title":"JAK protein kinase inhibitors","volume":"18","author":"Thompson","year":"2005","journal-title":"Drug News & Perspectives"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0167|cit167","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for Trial Sequential Analysis (TSA). 2011 http:\/\/ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"issue":"10","key":"10.1002\/14651858.CD010298.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"e25491","DOI":"10.1371\/journal.pone.0025491","article-title":"The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study","volume":"6","author":"Thorlund","year":"2011","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0169|cit169","doi-asserted-by":"crossref","unstructured":"Twombly R Small study on industry trial sponsorship leads to big questions about quality and bias Journal of the National Cancer Institute 2007 988 90","DOI":"10.1093\/jnci\/djm057"},{"issue":"12","key":"10.1002\/14651858.CD010298.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.leukres.2009.06.001","article-title":"How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis","volume":"33","author":"Vannucchi","year":"2009","journal-title":"Leukemia Research"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1017\/S1462399411002043","article-title":"Normal and malignant megakaryopoiesis","volume":"13","author":"Wen","year":"2011","journal-title":"Expert Reviews in Molecular Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7644","key":"10.1002\/14651858.CD010298.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010298.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"d7995","DOI":"10.1136\/bmj.d7995","article-title":"The idolatry of the surrogate","volume":"343","author":"Yudkin","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010298.pub2-BIB0175|cit175","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010298","article-title":"Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis (Protocol)","author":"Mart\u00ed-Carvajal","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD010298.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T03:18:01Z","timestamp":1723691881000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010298.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,10]]},"references-count":175,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010298.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,10]]}}}